Patients are asking how Crohn’s and colitis breakthroughs are going to impact their quality of life now and down the road, and the Crohn’s & Colitis Foundation’s March 30 teleconference will help answer these questions.
New York, NY (Vocus) March 10, 2010
Research in inflammatory bowel diseases (IBD) is changing and improving the way Crohn’s disease and ulcerative colitis—chronic and often debilitating digestive diseases impacting 1.4 million Americans—are diagnosed and treated. On Tuesday, March 30, at 1 PM ET , Crohn’s and colitis patients, families, and caregivers can tune into a Crohn’s & Colitis Foundation of America (CCFA) interactive educational webcast/teleconference entitled, “Breakthroughs in IBD Research: Helping You Today.” National expert and researcher Stephan R. Targan, MD, Director of the Inflammatory Bowel and Immunobiology Research Institute at Cedars-Sinai Medical Center, will discuss recent advances in IBD research and answer audience questions during an interactive question and answer session
During the program, participants will receive insight into important questions about research in inflammatory bowel diseases including:
o What is currently going on in research, how close are we to answers?
o How will advances in IBD genetics and immunology impact me?
o When should an infusion or injection therapy be considered in IBD treatment?
o What are clinical trials and how can they benefit me?
Board certified in internal medicine, gastroenterology and infectious disease, Dr. Targan has been awarded investigative grants from the National Institutes of Health (NIH), CCFA’s Scientific Achievement Award for Clinical Science, as well as research contracts with numerous industry sponsors. His research has primarily focused on the genetic and immunopathologic mechanisms of inflammatory bowel disease.
"Research into Crohn’s disease and ulcerative colitis is rapidly advancing, allowing for better therapies for patients today and tomorrow,” says Dr. Targan. “Patients are asking how Crohn’s and colitis breakthroughs are going to impact their quality of life now and down the road, and the Crohn’s & Colitis Foundation’s March 30 teleconference will help answer these questions.”
Shire is sponsoring this event. Registration is available at no cost to participants via an online portal at http://www.ccfa.org/webcasts/research and by phone at 1-877-547-5641 ext. 312.
About Crohn’s Disease & Ulcerative Colitis
Crohn’s disease and ulcerative colitis are painful, medically incurable illnesses that attack the digestive system. Crohn’s disease may attack anywhere from the mouth to the anus, while ulcerative colitis inflames only the large intestine (colon). Symptoms may include abdominal pain, persistent diarrhea, rectal bleeding, fever and weight loss. Many patients require hospitalization and surgery. These illnesses can cause severe complications, including colon cancer in patients with long-term disease. Some 1.4 million American adults and children suffer from Crohn’s disease or ulcerative colitis, with as many as 150,000 under the age of 18. Most people develop the diseases between the ages of 15 and 35.
About the Crohn’s & Colitis Foundation
The Crohn’s & Colitis Foundation of America’s mission is to cure Crohn’s disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. The Foundation ranks third among leading health non-profits in the percentage of expense devoted to research toward a cure, with more than 81 cents of every dollar the Foundation spends goes to mission-critical programs. The Foundation consistently meets the standards of organizations that monitor charities, including the Better Business Bureau’s Wise Giving Alliance (give.org) and the American Institute of Philanthropy (charitywatch.org). For more information, contact the Foundation at 800-932-2423 or visit http://www.ccfa.org. Join CCFA on Facebook at http://apps.facebook.com/supportccfa/ and follow CCFA on Twitter at http://www.twitter.com/ccfa.
Shire is a leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician, and focuses on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases. For further information on Shire, visit http://www.shire.com.